Det är viktigt för oss våra produkter verkligen ger dig

effekt. Det är även viktigt att man är ödmjuk och förstår att snarkning är mycket svårt. Därför erbjuder  vi en totallösning som omfattar både näsa och svalg.

Ingen vet om det är näsan som är problemet. Eller om det växlar under natten. Men det vi vet är att det bara är problem på två ställen. Näsan och svalget. Vidgar man dessa passager är det bäst chans att lyckas.

För att du skall kunna kolla detta har vi utvecklat det första Sömnlabbet för iPhone i världen. Det är perfekt

för att kolla sina problem och en bra hjälp om man vill

forma om ReduZnore.

 ReduZnore

Publicerad på Sleep, Baltimore, världens största sömnforskarkongress.

Se Journal of Sleep & Sleep Disorders Research Vol.36 2013

WHAT IS THE IMPACT OF AN OVER-THE-COUNTER SOFT ORAL APPLIANCE ON SNORING AND MILD BREATHING DISORDER?

Bader, Sediqi, University of Gothenburg, Gothenburg, Sweden.

SDS Kliniken, Gothenburg. Sweden

Results: At first PG. the mean snoring indexfwas 35 (SD 27) and AHI10 (SD 11). Twenty three patients discontinued the study: 14 due to lack of time. etc. 9 (19%) due to adverse side effects: pain (7). allergic reaction (1). salivation (1). Subjective assessment was given by 28 patients (25 completed both PG. 3 withdrew before 2d PG): 61% were satisfied, 50% thought that it fit well, 32% experienced poor fit: 89 % found it helpful, while 4% were negative: 43% found it comfortable. 46% thought it was hard. 11% soft. Many patients (35 %) experienced transient side effects, mainly tension / pain. Habituation time could be> 1 week. Subjective sleep quality improved (about 50%) progressively from the first to the third week. PG showed that after 3 weeks 52 % had significantly reduced snoring (P = 0.001). and 24% had reduced AHI (P = 0029). Men were more responsive than women but had also more pronounced problems.

Conclusion: This type of OTC splint applied on adequate patients might have a positive impact on snoring and sleep quality with a better response the more pronounced is the disorder. Side effects decrease with time, probably in relation to habituation period and better adaptation.

MegaVent

Internal nasal dilator (Megavent) in the treatment of snoring

Chairat Nirantarat M.D., Maneenuch chantachaeng M.D. Ophthalmology and Otolaryngology Department Faculty of Medicine

Result The average age of samples is 44.5±11.4 years, average BMI is 25.0±3.9 kg/m2 and having snore for 2.3± 3.6 years. Using nasal dilator Megavent® in test group can significantly reduce snoring and drowsiness during a day (-2.40±2.38 VS -0.13±2.11, p<0.001), respectively. Compared to control group, using nasal dilator Megavent® can significantly reduce snoring (-2.40±2.38 VS -0.13±2.11, p< 0.001. 24 out of 30 participants (80.0%) in test group significantly reduced their snoring when using nasal dilator Megavent®. 43.3% (13 out of 30 participants in test group) reduced snoring with more than 50%. On the other hand, there was 14 out of 30 participants in control group could reduce snoring at 46.7% (14 out of 30 participants) and there was only 3.3% who reduced snoring over 50% (1 out of 30 participants in control group). The evaluation of the rate of sleep apnea/hypopnea (AHI) in test group showed there was 6 out of 30 tested participants or 20% who reduced sleep apnea/hypopnea while the control group had only 3.3% (1 out of 30 participants in control group) reduced sleep apnea/hypopnea.

Summary Using nasal dilator Megavent® can reduce snoring and drowsiness well. When comparing to control group, the study shows using nasal dilator Megavent® significantly reduce snoring and slightly reduce sleep apnea/hypopnea but there are not significantly reduced respiratory disturbance and oxygen de-saturation.

The study also shows that it is safe and easy to use nasal dilator Megavent® without any complication.